Understanding Advances Shaping Precision Medicine for Generalized Myasthenia Gravis Marco Meglio

Published Date: 03 Nov 2026

Shaida Khan, DO, associate professor of neurology at UT Southwestern Medical Center, reflected on a recent NeurologyLive Clinical Forum on generalized myasthenia gravis and discussed how FcRn and complement inhibitors are reshaping treatment algorithms for the disease.

Read Full News

Latest News

Examining Trontinemab in Early Alzheimer Disease: The Phase 3 TRONTIER 1 and 2 Trials Isabella Ciccone, MPH

The phase 3 TRONTIER 1 and 2 trials will test whether trontinemab's faster brain entry and rapid amyloid clearance translate into slower clinical decline in early Alzheimer disease.

Episode 178: Evolving Approaches to Epilepsy Clinical Trial Design Isabella Ciccone, MPH, M. Scott Perry, MD, Marco Meglio

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with M. Scott Perry, MD. [LISTEN TIME: 15 minutes]

Insights on the Updated 2026 AHA/ASA Stroke Rehabilitation Guidelines Louie Pasculli, Talya Fleming, MD, Sara Cuccurullo, MD

Sara Cuccurullo, MD, FAAPMR, and Talya Fleming, MD, FAAPMR, of Hackensack Meridian JFK Johnson Rehabilitation Institute, discuss the updated adult stroke rehabilitation and recovery guidelines and their implications for clinical practice.

World Stroke Day 2026: Closing the Gap Between Stroke Onset and the Emergency Call Number Isabella Ciccone, MPH, Brian Snelling, MD

Brian Snelling, MD, director of the stroke program at Marcus Neuroscience Institute discussed delays in calling 911 after stroke onset, gaps in awareness of atypical symptoms, and how to reach underserved populations.

Blood-Based Biomarkers for Monitoring Treatment Response in Multiple Sclerosis Louie Pasculli, Kim Henriksen, PhD

Kim Henriksen, PhD, discusses research evaluating blood-based biomarkers of blood-brain barrier remodeling and immune cell activity in multiple sclerosis, including their potential to track treatment responses and inform future biomarker development.

World Stroke Day: Preventing Perioperative Stroke With Predictive Tools Marco Meglio, Shadi Yaghi, MD

Shadi Yaghi, MD, FAHA, Chair of Neurology at Hackensack Meridian Neuroscience Institute at Jersey Shore University Medical Center, discusses a new calculator that predicts stroke risk within 30 days of a procedure.

Todays Updates

AI Could Help Find Undiagnosed COPD on Lung Cancer Screening CT Jean Bourbeau, MD

Jean Bourbeau, MD, says AI analysis of CT scans is not ready for routine use but could reshape early COPD diagnosis as GOLD expands its AI guidance.

Inhaled Treprostinil Reduces Recurrent IPF Events, With Steven Nathan, MD Steven D. Nathan, MD, FCCP

A TETON-2 post hoc analysis at CHEST 2026 found 126 progression events with inhaled treprostinil vs 161 with placebo across 52 weeks.

Voceryq Gains FDA Accelerated Approval for Recurrent Respiratory Papillomatosis

Voceryq Gains FDA Accelerated Approval for Recurrent Respiratory Papillomatosis

NeurologyLive® Friday 5 — October 30, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 30, 2026.

Distinguishing Lambert-Eaton Myasthenic Syndrome From Myasthenia Gravis: Ocular and Systemic Clues Isabella Ciccone, MPH

Although ocular signs in LEMS are typically mild and appear late, recognizing them alongside proximal weakness and autonomic symptoms can speed diagnosis and earlier detection of an associated lung cancer.

Balcinrenone Plus Dapagliflozin Lowers BP, With Adriana Marton, MD

Balcinrenone Plus Dapagliflozin Lowers BP, With Adriana Marton, MD

VA Dialysis Tied to Lower Mortality, With Virginia Wang, PhD, MSPH

VA Dialysis Tied to Lower Mortality, With Virginia Wang, PhD, MSPH

Todays Updates

AI Could Help Find Undiagnosed COPD on Lung Cancer Screening CT Jean Bourbeau, MD

Jean Bourbeau, MD, says AI analysis of CT scans is not ready for routine use but could reshape early COPD diagnosis as GOLD expands its AI guidance.

Inhaled Treprostinil Reduces Recurrent IPF Events, With Steven Nathan, MD Steven D. Nathan, MD, FCCP

A TETON-2 post hoc analysis at CHEST 2026 found 126 progression events with inhaled treprostinil vs 161 with placebo across 52 weeks.

Voceryq Gains FDA Accelerated Approval for Recurrent Respiratory Papillomatosis

Voceryq Gains FDA Accelerated Approval for Recurrent Respiratory Papillomatosis

NeurologyLive® Friday 5 — October 30, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 30, 2026.

Distinguishing Lambert-Eaton Myasthenic Syndrome From Myasthenia Gravis: Ocular and Systemic Clues Isabella Ciccone, MPH

Although ocular signs in LEMS are typically mild and appear late, recognizing them alongside proximal weakness and autonomic symptoms can speed diagnosis and earlier detection of an associated lung cancer.

Balcinrenone Plus Dapagliflozin Lowers BP, With Adriana Marton, MD

Balcinrenone Plus Dapagliflozin Lowers BP, With Adriana Marton, MD

VA Dialysis Tied to Lower Mortality, With Virginia Wang, PhD, MSPH

VA Dialysis Tied to Lower Mortality, With Virginia Wang, PhD, MSPH

Latest News

The phase 3 TRONTIER 1 and 2 trials will test whether trontinemab's faster brain entry and rapid amyloid clearance translate into slower clinical decline in early Alzheimer disease.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with M. Scott Perry, MD. [LISTEN TIME: 15 minutes]

Sara Cuccurullo, MD, FAAPMR, and Talya Fleming, MD, FAAPMR, of Hackensack Meridian JFK Johnson Rehabilitation Institute, discuss the updated adult stroke rehabilitation and recovery guidelines and their implications for clinical practice.

Brian Snelling, MD, director of the stroke program at Marcus Neuroscience Institute discussed delays in calling 911 after stroke onset, gaps in awareness of atypical symptoms, and how to reach underserved populations.

Kim Henriksen, PhD, discusses research evaluating blood-based biomarkers of blood-brain barrier remodeling and immune cell activity in multiple sclerosis, including their potential to track treatment responses and inform future biomarker development.

Shadi Yaghi, MD, FAHA, Chair of Neurology at Hackensack Meridian Neuroscience Institute at Jersey Shore University Medical Center, discusses a new calculator that predicts stroke risk within 30 days of a procedure.

News All Time

CAR-T Agent Zola-cel Shows No New Multiple Sclerosis Disease Activity in Phase 1 Study Louie Pasculli

Updated data from Breakfree-2 study showed that treatment with a single zola-cel infusion achieved NEDA-3 in highly active relapsing multiple sclerosis and led to mostly stable disability in progressive multiple sclerosis.

NeurologyLive® Brain Games: October 25, 2026 Louie Pasculli, Marco Meglio

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is recent advances in gene therapies.

Tenecteplase Benefit Before Thrombectomy Varies by Stroke Cause, Study Shows Marco Meglio

A secondary analysis of the BRIDGE-TNK trial found tenecteplase before thrombectomy improved functional outcomes in cardioembolic but not atherosclerotic stroke.

Houston Forum Highlights Awareness Gaps in NF1 Plexiform Neurofibroma Care Marco Meglio

At a NeurologyLive and Targeted Oncology Clinical Forum in Houston, Kevin J. Bielamowicz, MD, of Arkansas Children’s Hospital, discussed how incidental diagnosis and limited awareness of systemic therapy continue to delay care for patients with NF1-associated plexiform neurofibromas.

Remibrutinib Lowers Relapse Rate vs Teriflunomide in Relapsing MS Matt Hoffman, Louie Pasculli

Phase 3 data show the oral BTK inhibitor reduced annualized relapse rate by 35.2% and 31.2% vs teriflunomide, with no liver safety signal or Hy's Law cases.

NeurologyLive® Friday 5 — October 23, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 23, 2026.

Endovascular Therapy Benefit in Distal Vessel Stroke Tied to Severity, Not IVT Status Marco Meglio

A secondary analysis of the DISTAL trial found endovascular therapy's benefit depended more on stroke severity than on prior thrombolysis treatment.

More Time in Target Blood Pressure Range Cuts Recurrent Stroke After Intracerebral Hemorrhage Marco Meglio

A pooled analysis of 4 randomized trials found that more time with blood pressure below 130 mmHg after intracerebral hemorrhage reduced recurrent stroke risk.

FDA Accepts Troriluzole NDA Resubmission for Spinocerebellar Ataxia Marco Meglio

The FDA set a first quarter 2027 goal date for troriluzole in spinocerebellar ataxia and plans an advisory committee after a 2025 complete response letter.

Liposomal Mitoxantrone Shows Early Safety Signal in Phase 2 NMOSD Trial Marco Meglio

A phase 2 trial found liposomal mitoxantrone hydrochloride had an acceptable safety profile and a potential trend toward fewer relapses in neuromyelitis optica spectrum disorder.

New Phase 2 Trial Evaluates Fenebrutinib Dosing in Children With Relapsing MS Louie Pasculli

The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS.

Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated Marco Meglio

Data from the real-world, CONFIDENCE study found switching from intravenous to subcutaneous ocrelizumab was well tolerated in patients with relapsing and primary progressive MS.

NeuroVoices: Bruce Bebo, PhD, on Big Bets for Breakthroughs and the Campaign to End MS Bruce Bebo, PhD, Isabella Ciccone, MPH

The chief research and medical affairs officer at the National MS Society discussed AI-enabled imaging, biomarkers of progression, women's health across the lifespan, and the Society's Campaign to End MS.

Divozilimab Cuts Relapse Risk at 1 Year in Phase 3 AQUARELLE Trial of NMOSD Marco Meglio

One-year data from the phase 3 AQUARELLE study found that divozilimab, an anti-CD20 antibody, reduced relapse risk in patients with neuromyelitis optica spectrum disorder.

CALLIPER Extension Data Show Sustained Disability Outcomes With Vidofludimus Calcium in Progressive MS Isabella Ciccone, MPH

Open-label extension data showed that disability trends observed with vidofludimus calcium during the double-blind period of the phase 2 CALLIPER trial persisted with continued treatment in progressive MS.

FDA Grants Fast Track to AV-1959R for Alzheimer Prevention Matt Hoffman

Fast Track status covers AV-1959R, an investigational amyloid-beta vaccine, for preventing Alzheimer disease in cognitively unimpaired adults with amyloid pathology.

Recommended News For You

Which Salvage Therapy Is Best for Recurrent Prostate Cancer?

FDA Declines to Approve Achieve Life Sciences' Smoking-cessation Drug

Five-year survival in patients with unresectable hepatocellular carcinoma sets milestone

Top Cancer Centers; Phase III Win in Prostate Cancer; Screening Recs for Anal Cancer

Researchers have determined that malignancy hibernation will be the next front in the fight against breast cancer.

Chemo-Free Triplet Yields 68% Response Rate in Richter Transformation

Study Questions How Prostate Cancer Focal Therapy Is Being Used

Recommended Articles For You

Expanding Oncology Frontiers: Rare Cancers, Breakthroughs, and Precision Medicine Advances 

Evidence-Based Insights in Oncology for Specialists 

The Role of Alanine Aminotransferase in Liver Health and Disease  

Trends in Incidence, Care, and Surgery for Medullary Thyroid Cancer: A Review 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The diamonds that could find cancer

2.

Photoacoustic spectral analysis for gaining knowledge of the tumor microenvironment.

3.

If CD19 CAR T-Cell Therapy Fails in Lymphoma, Try a CD22 Version

4.

NEJM: Pirtobrutinib is effective in CLL patients who have received prior BTK inhibitor therapy.

5.

GuCS Video Pearls: Video Pearls from the Genitourinary Cancers Symposium

1.

Molecular Subtyping for Individualized Cancer Care

2.

Mechanisms of Tumor–Stromal Communication During Cancer Progression

3.

Unlocking the Potential of Red Bone Marrow in the Formation of Blood Cells

4.

The Latest Causes and Symptoms of Bowen's Disease: All You Need to Know 

5.

Age-Dependent Hematopoietic Stem Cell Dynamics

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion

2.

Virtual Case Study on Elephantiasis of Lower Limb- An Initiative by Hidoc Dr.

3.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III

4.

Understanding Early Relapse in B-cell ALL: Rates, Risks, and Common Sites

5.

A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot